OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

PLoS Medicine

Volumn 3, Issue 11, 2006, Pages 2131-2144

  Matsumoto, Makoto ^a   Hashizume, Hiroyuki ^a   Tomishige, Tatsuo ^a   Kawasaki, Masanori ^a   Tsubouchi, Hidetsugu ^b   Sasaki, Hirofumi ^b   Shimokawa, Yoshihiko ^c   Komatsu, Makoto ^b  

^a Microbiological Research Institute   (Japan)

^b Medicinal Chemistry Research Institute   (Japan)

^c Tokushima Research Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTIRETROVIRUS AGENT; BCG VACCINE; CGI 17341; CYTOCHROME P450; ETHAMBUTOL; ISONIAZID; MYCOLIC ACID; OPC 67683; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; DELAMANID; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TUBERCULOSIS; ANIMAL; BLOOD; CELL LINE; DRUG ANTAGONISM; INTRACELLULAR MEMBRANE; MACROPHAGE; MAMMAL; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; TREATMENT OUTCOME;

ANIMALS; ANTITUBERCULAR AGENTS; BLOOD; CELL LINE; HUMANS; INTRACELLULAR MEMBRANES; MACROPHAGES; MAMMALS; MICE; MICROBIAL SENSITIVITY TESTS; MICROSOMES, LIVER; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; MYCOLIC ACIDS; NITROIMIDAZOLES; OXAZOLES; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 33845323336     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030466     Document Type: Article

References (38)

1. World Health Organization (1999) Removing obstacles to healthy development. Geneva: World Health Organization.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282: 677-686.
3. Dolin PJ, Raviglione MC, Kochi A (1994) Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 72: 213-220.
4. Espinal MA (2003) The global situation of MDR-TB. Tuberculosis (Edinb) 83: 44-51.
5. Farmer PE, Kononets AS, Borisov SE, Goldfarb A, Healing T, et al. (1999) Recrudescent tuberculosis in the Russian Federation. In: Farmer PE, Reichman LB, Iseman MD editors. The global impact of drug resistant tuberculosis. Boston (Massachusetts): Harvard Medical School/Open Society Institute.
6. WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance (2000) Anti-tuberculosis drug resistance in the world. Report No. 2: Prevalence and trends. Geneva: World Health Organization. 253 p.
7. Global Alliance for TB Drug Development (2002-2003) Annual Report. Available: http://www.tballiance.org/pdf/TBA_annual_2002-2003.pdf. Accessed 31 October 2006.
8. Raether W, Hanel H (2003) Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res 90: S19-S39.
9. Ashtekar DR, Costa-Perira R, Nagrajan K, Vishvanathan N, Bhatt AD, et al. (1993) In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 37: 183-186.
10. Nagarajan K, Shankar RG, Rajappa S, Shenoy ST, Costa-Pereira R (1989) Nitroimidazoles XXI 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles with antitubercular activity. Eur J Med Chem 24: 631-633.
11. Matsumoto M, Hashizume H, Tsubouchi H, Sasaki H, Itotani M, et al. (2006) Screening for novel antituberculosis agents that are effective against multidrug resistant tuberculosis. Washington (D. C.): ACS Books. In press.
12. Saito H, Sato K, Tomioka H, Dekio S (1995) In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tuber Lung Dis 76: 377-380.
13. Sato K, Akaki T, Tomioka H (1998) Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. J Antimicrob Chemother 41: 77-83.
14. Woods GL, Brown-Elliott BA, Desmond EP, Hall GS, Heifets L, et al. (2002) Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic actinomycetes. Clinical and Laboratory Standards Institute 20: 18.
15. Emoto C, Yamazaki H, Iketaki H, Yamasaki S, Satoh T, et al. (2001) Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. Xenobiotica 31: 265-275.
16. Ikeda T, Nishimura K, Taniguchi T, Yoshimura T, Hata T, et al. (2001) In vitro evaluation of drug interaction caused by enzyme inhibition. Xenobio Metabol and Dispos 16: 115-126.
17. Umehara K, Shimokawa Y, Miyamoto G (2002) Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol Pharm Bull 25: 682-685.
18. Correia MA (1995) Rat and human liver cytochrome P450: Substrate and inhibitor specificities and functional markers. In: Ortiz de Montellano PR editor. Cytochrome P450: Structure, mechanism, and biochemistry. New York: Plenum Press. pp. 607-630.
19. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, et al. (1990) Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 29: 651-663.
20. Stevens JC, White RB, Hsu SH, Martinet M (1997) Human liver CYP2B6-catalyzed hydroxylation of RP 73401. J Pharmacol Exp Ther 282: 1389-1395.
21. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW (1994) Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54: 5543-5546.
22. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, et al. (1992) Hydroxylation of warfarin by human cDNA expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5: 54-59.
23. Inaba T, Jurima M, Mahon WA, Kalow W (1985) In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin phydroxylase and sparteine monooxygenase. Drug Metab Dispos 13: 443-448.
24. Broly F, Libersa C, Lhermitte M, Bechtel P, Dupuis B (1989) Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 28: 29-36.
25. Guengerich FP, Kim DH, Iwasaki M (1991) Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4: 168-179.
26. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, et al. (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25: 261-270.
27. Matsumiya T, Yamato K, Ryu C (1985) . [Studies on the blood level of RFP and new administration method of RFP in relation to other antituberculous drugs] [Article in Japanese] Kekkaku 60: 483-494.
28. Israili ZH, Rogers CM, el-Attar H (1987) Pharmacokinetics of antituberculosis drugs in patients. J Clin Pharmacol 27: 78-83.
29. Zhu M, Starke JR, Burman WJ, Steiner P, Stambaugh JJ (2002) Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 22: 686-695.
30. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544.
31. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966.
32. Manjunatha UH, Boshoff H, Dowd CS, Zhang L, Albert TJ, et al. (2006) Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 103: 431-436.
33. Edwards DI (1993) Nitroimidazole drugs - Action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 31: 9-20.
34. Shen WW (1995) Cytochrome P450 monooxygenases and interactions of psychotropic drugs: A five-year update. Int J Psychiatry Med 25: 277-290.
35. Riesenman C (1995) Antidepressant drug interactions and the cytochrome P450 system: A critical appraisal. Pharmacotherapy 15: 84S-99S.
36. Somogyi A, Muirhead M (1987) Pharmacokinetic interactions of cimetidine 1987. Clin Pharmacokinet 12: 321-366.
37. Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, et al. (1997) Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: Evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact 107: 17-30.
38. Hampton T (2005) TB drug research picks up the pace. JAMA 293: 2705-2707.